Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer (Investigational New Drugs DOI: 10.1007/s10637-013-0062-5)

Carolyn D. Britten, Alex A. Adjei, Robert Millham, Brett E. Houk, Gary Borzillo, Kristen Pierce, Zev A. Wainberg, Patricia M. LoRusso

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer (Investigational New Drugs DOI: 10.1007/s10637-013-0062-5)'. Together they form a unique fingerprint.